Entrada Therapeutics

DTX Pharma

This biotechnology firm develops RNA-based therapeutics for patients with rare neuromuscular and central nervous system disorders using a proprietary fatty acid delivery platform.

Dyne

This company develops therapeutics for patients with genetically driven neuromuscular diseases.

Ensoma

This company develops in vivo genomic medicines and vector delivery platforms to engineer blood and immune cells for patients with genetic diseases and cancer.

EdiTy Therapeutics

This company develops immune cell delivery platforms to transport therapeutic proteins into diseased cells for patients with cancer and genetic disorders.

Evox Therapeutics

This biotechnology company develops engineered exosome therapeutics to deliver genetic medicines and proteins for patients with rare diseases and neurological disorders.

Dyne Therapeutics

The company develops oligonucleotide therapeutics to treat patients with genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1.

Aera Therapeutics

This biotechnology company develops delivery platforms for genetic medicines to treat various diseases for biopharmaceutical partners and patients.

Shape Therapeutics

The company develops programmable RNA medicines and delivery systems for patients with genetic disorders and other hard-to-treat diseases.